Abstract
Background: Diabetic foot syndrome (DFS) and coronary artery disease (CAD) are two of the most devastating complications of type 2 diabetes mellitus (T2DM), frequently coexisting and interacting through overlapping vascular, metabolic, and inflammatory pathways. Understanding their pathophysiological interdependence is essential for effective management of high-risk diabetic populations.
Methods: This narrative review synthesizes current literature on shared mechanisms linking DFS and CAD, including endothelial dysfunction, atherogenesis, systemic inflammation, and impaired microcirculation. Emphasis is placed on epidemiological data, cardiovascular risk stratification, and clinical outcomes in patients with combined DFS and CAD.
Results: T2DM accelerates atherosclerosis and promotes multivessel coronary involvement, while also contributing to peripheral ischemia and neuropathy characteristic of DFS. Chronic hyperglycemia, oxidative stress, dyslipidemia, and platelet hyperreactivity play central roles in both coronary and peripheral artery disease. Patients with both conditions exhibit significantly higher rates of amputation, cardiac events, and mortality, underscoring the need for integrative management approaches.
Conclusion: DFS and CAD share a common pathophysiological foundation and should be regarded as manifestations of systemic diabetic angiopathy. Risk prediction and treatment strategies must account for the bidirectional impact of these conditions. Early cardiovascular screening in DFS patients and individualized vascular intervention planning are essential to improve limb and life prognosis.
References
Beckman JA, Creager MA. Vascular complications of diabetes. Circ Res. 2016;118(11):1771–85.
Hinchliffe RJ, Brownrigg JR, Apelqvist J, et al. IWGDF Guidelines on the diagnosis, prognosis and management of peripheral artery dis-ease in diabetes. Diabetes Metab Res Rev. 2020;36(S1):e3276.
Stehouwer CD. Microvascular dysfunction and hyperglycemia: a vi-cious cycle with widespread consequences. Diabetes. 2018;67(9):1729–41.
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on di-abetes, pre-diabetes and cardiovascular diseases. Eur Heart J. 2020;41(2):255–323.
Boulton AJM. The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes Metab Res Rev. 2008;24(S1):S3–6.
Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes: a review. Diabet Med. 2010;27(1):4–14.
Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–70.
Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993;328(23):1676–85.
Nicholls SJ, Tuzcu EM, Kalidindi S, et al. Effect of diabetes on pro-gression of coronary atherosclerosis and arterial remodeling. J Am Coll Cardiol. 2008;52(21):1675–80.
Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376(24):2367–75.
Albers GW, Amarenco P, Easton JD, et al. Antithrombotic therapy in patients with peripheral artery disease. Circulation. 2014;129(14):1425–42.
Vahabzadeh M, Zhan LX, Mills JL. The diabetic foot syndrome. Surg Clin North Am. 2013;93(4):859–93.
Saely CH, Rein P, Drexel H. The metabolic syndrome and risk of cardiovascular disease. J Clin Endocrinol Metab. 2007;92(2):398–404.
Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet. 2003;361(9368):1545–51.
de Vries M, Ouwens DM, Strijder C, et al. Cardiovascular disease in diabetes: the role of glycemic control, inflammation and lipids. Vasc Pharmacol. 2020;133:106733.